📰 Solid Tumors News
Page 37 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
March 28, 2023
Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) have earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 […]
March 6, 2023
/PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment...
March 3, 2023
Operator: Hello and welcome to the Fulgent Genetics Q4 and Fiscal Year 2022 Earnings Conference Call and Webcast. As a reminder, this conference is being recorded.
February 27, 2023
27.02.2023 - Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805 (KRASG12D) expected to begin clinical development ...
February 24, 2023
New Delhi [India], February 24 (ANI/NewsVoir): The 21st edition of RGCON, one of the largest annual international conferences on cancer in the country, will be held from Feb 24-26, 2023 at New Delhi. The theme of this year's conference is "Curing Cancer in Children and Adolescents". With 80% of the children with cancer living in low and medium income countries, RGCON 2023 intends to set the agenda for managing childhood cancer in the country. Over 200 national faculties from all le...
February 19, 2023
Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) gapped up prior to trading on Friday . The stock had previously closed at $11.99, but opened at $12.31. Kura Oncology shares last traded at $12.03, with a volume of 42,266 shares trading hands. Analysts Set New Price Targets A number of equities analysts have commented […]
February 13, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology...
February 8, 2023
- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 -- Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 -- GAAP Diluted EPS of $(0.09) for the Fourth Quarter of 2...
January 26, 2023
/PRNewswire/ -- A latest research report [115+] pages with 360-Degree visibility, titled "Minimal Residual Disease Market Share, Size, Trends, Industry...
January 26, 2023
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an...